Biomarkers are objective and quantifiable characteristics of biological processes that can be measured in the body and are related to the incidence of the outcome of disease. They do not necessarily correlate with a patient’s experience of well-being. We can consider surrogate endpoints only in a small subset of well-characterized biomarkers, with well-evaluated clinical relevance, and with statistical inference between their changes and outcomes. Phoniatrics is the medical discipline regarding the normal, pathological, and professional processes of communication (voice, speech, language, and hearing) and swallowing. The glottis has three important and highly relevant functions: breathing, phonation, and airway protection. Voice-related biomarkers are features of the voice that are associated with clinical outcomes and can be used to monitor patients’ health status, diagnose a condition, or grade the severity or stages of a disease. The advancement of digital technologies and the development of remote health care greatly progressed during the global pandemic in 2019 and promoted the expansion of voice-related biomarkers because of their noninvasive, accessible, and low-cost collection and recording capability via computers or smartphones. Despite this, there are still no digital biomarkers currently approved by the FDA. The Biomarker Committee of the Union of European Phoniatricians is a new entity with the aim of developing knowledge about digital technologies regarding characteristic voice features in different disorders and defining easily accessible parameters with the potential of leading to biomarkers for glottal closure.